Harrow (HROW) Total Current Liabilities (2010 - 2026)
Harrow's (HROW) quarterly Total Current Liabilities came in at $91.4 million in Q1 2026, down 51.1% year-on-year from $187.0 million in Q1 2025, and down 5.05% quarter-over-quarter from $96.3 million in Q4 2025.
Harrow (HROW) Total Current Liabilities (2010 - 2026) Analysis & Trends
Harrow's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $91.4 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 51.1% year-over-year to $91.4 million in Q1 2026; TTM through Mar 2026 was $91.4 million, a 51.1% decrease from a year earlier, with the FY2025 full-year figure at $96.3 million, up 5.43% from the prior year.
- Total Current Liabilities slipped to $91.4 million in Q1 2026 per HROW's latest filing, from $96.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $248.9 million in Q2 2025 and bottomed at $9.2 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $49.3 million (2023), against an average of $67.0 million.
- Across the five-year window, Total Current Liabilities surged 399.26% in 2024 and tumbled 51.1% in 2026, its largest moves.
- Year by year, Total Current Liabilities stood at $18.6 million in 2022, then soared by 164.83% to $49.3 million in 2023, then soared by 85.11% to $91.3 million in 2024, then grew by 5.43% to $96.3 million in 2025, then decreased by 5.05% to $91.4 million in 2026.
- Per Business Quant, the three latest HROW Total Current Liabilities figures stand at $91.4 million (Q1 2026), $96.3 million (Q4 2025), and $65.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 91.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.44 Mn |
| Dec 31, 2025 | 96.30 Mn |
| Sep 30, 2025 | 65.40 Mn |
| Jun 30, 2025 | 248.88 Mn |
| Mar 31, 2025 | 186.99 Mn |
| Dec 31, 2024 | 91.34 Mn |
| Sep 30, 2024 | 95.01 Mn |
| Jun 30, 2024 | 53.55 Mn |
| Mar 31, 2024 | 41.75 Mn |
| Dec 31, 2023 | 49.34 Mn |
| Sep 30, 2023 | 19.03 Mn |
| Jun 30, 2023 | 23.01 Mn |
| Mar 31, 2023 | 17.71 Mn |
| Dec 31, 2022 | 18.63 Mn |
| Sep 30, 2022 | 18.37 Mn |
| Jun 30, 2022 | 12.92 Mn |
| Mar 31, 2022 | 9.18 Mn |
| Dec 31, 2021 | 9.72 Mn |
| Sep 30, 2021 | 10.48 Mn |
| Jun 30, 2021 | 8.14 Mn |